AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16473225 — intervention group
Group type: EXPERIMENTAL
Intervention: AcrySof Natural intraocular lens (IOL)
Number of subjects: 30
Study 16473225 — intervention group
Group type: COMPARATOR
Intervention: AcrySof SA60AT intraocular lens (control group)
Number of subjects: 30
Study 12429360 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine 40 mg/day
Number of subjects: 60
Study 12429360 — intervention group
Group type: COMPARATOR
Intervention: Paroxetine 20 mg/day plus amisulpride 50 mg/day
Number of subjects: 60
Study 10889816 — intervention group
Group type: EXPERIMENTAL
Intervention: IDEIA PCE chlamydia
Number of subjects: 380
Study 10889816 — intervention group
Group type: COMPARATOR
Intervention: Amplicor PCR
Number of subjects: 380
Study 10889816 — intervention group
Group type: COMPARATOR
Intervention: PCR and IDEIA PCE
Number of subjects: 380
Study 8638831 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide at concentrations of 0, 20, 40, 60, and 75 vol%
Number of subjects: 25
Study 8638831 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 25
Study 1460750 — intervention group
Group type: EXPERIMENTAL
Intervention: Enflurane (1.49 MAC hours)
Number of subjects: 27
Study 1460750 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane (2.17 MAC hours)
Number of subjects: 27
Study 1460750 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane (1.29 MAC hours)
Number of subjects: 27
Study 6330716 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine (150 mg twice daily)
Number of subjects: 53
Study 6330716 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 31067358 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose interferon-α (HDI)
Number of subjects: 2000
Study 29110140 — intervention group
Group type: EXPERIMENTAL
Intervention: IDgenetix®
Number of subjects: 0
Study 29110140 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 0
Study 29110140 — intervention group
Group type: EXPERIMENTAL
Intervention: IDgenetix® in patients with severe depression
Number of subjects: 0
Study 26689590 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital home ovulation tests (OTs)
Number of subjects: 36
Study 26689590 — intervention group
Group type: COMPARATOR
Intervention: Advice to have intercourse every 2-3 days
Number of subjects: 36
Study 23763990 — intervention group
Group type: EXPERIMENTAL
Intervention: Paired associative stimulation (PAS) with unspecific attention control
Number of subjects: 10
Study 23763990 — intervention group
Group type: EXPERIMENTAL
Intervention: Paired associative stimulation (PAS) with specific electrical attention control
Number of subjects: 10
Study 23763990 — intervention group
Group type: EXPERIMENTAL
Intervention: Paired associative stimulation (PAS) with visual attention focus
Number of subjects: 10
Study 22196464 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic transfusion of FFP omitted
Number of subjects: 0
Study 22196464 — intervention group
Group type: COMPARATOR
Intervention: Transfusion of a fixed dose of 12 ml/kg of FFP
Number of subjects: 0
Study 19595251 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymosin alpha(1) Group (n = 23)
Number of subjects: 91
Study 19595251 — intervention group
Group type: EXPERIMENTAL
Intervention: CBP Group (n = 22)
Number of subjects: 91
Study 19595251 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Therapy Group (n = 22)
Number of subjects: 91
Study 19595251 — intervention group
Group type: COMPARATOR
Intervention: CBP Group, Combined Therapy Group, Thymosin alpha(1) Group
Number of subjects: 91
Study 16817289 — intervention group
Group type: EXPERIMENTAL
Intervention: Trillium-coated oxygenator (TC)
Number of subjects: 20
Study 16817289 — intervention group
Group type: COMPARATOR
Intervention: Non-coated oxygenator (NC)
Number of subjects: 20
Study 14508796 — intervention group
Group type: EXPERIMENTAL
Intervention: Methacholine
Number of subjects: 36
Study 14508796 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside
Number of subjects: 36
Study 14508796 — intervention group
Group type: EXPERIMENTAL
Intervention: NG‐monomethyl‐L‐arginine (L‐NMMA)
Number of subjects: 36
Study 14508796 — intervention group
Group type: COMPARATOR
Intervention: Flow-mediated dilation
Number of subjects: 36
Study 14508796 — intervention group
Group type: COMPARATOR
Intervention: Nitroglycerin-induced dilation
Number of subjects: 36
Study 14508796 — intervention group
Group type: COMPARATOR
Intervention: Antioxidant vitamin C
Number of subjects: 36
Study 14508796 — intervention group
Group type: COMPARATOR
Intervention: L-arginine
Number of subjects: 36
Study 11382368 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised group (directly observed isoniazid therapy twice weekly)
Number of subjects: 300
Study 11382368 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer group (daily self‐administered isoniazid with peer counseling and education)
Number of subjects: 300
Study 11382368 — intervention group
Group type: COMPARATOR
Intervention: Routine group (routine care)
Number of subjects: 300
Study 11382368 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate incentives
Number of subjects: 300
Study 11382368 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferred incentives
Number of subjects: 300
Study 11382368 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised group
Number of subjects: 300
Study 11382368 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer group
Number of subjects: 300
Study 11382368 — intervention group
Group type: COMPARATOR
Intervention: Routine group
Number of subjects: 300
Study 11382368 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer group (n = 27)
Number of subjects: 300
Study 11382368 — intervention group
Group type: COMPARATOR
Intervention: Routine group (n = 32)
Number of subjects: 300
Study 9233181 — intervention group
Group type: EXPERIMENTAL
Intervention: Event Monitor (EM)
Number of subjects: 11
Study 9233181 — intervention group
Group type: COMPARATOR
Intervention: Daily log
Number of subjects: 11
Study 9233181 — intervention group
Group type: COMPARATOR
Intervention: Recall method
Number of subjects: 11
Study 7952457 — intervention group
Group type: EXPERIMENTAL
Intervention: Suction group
Number of subjects: 80
Study 7952457 — intervention group
Group type: COMPARATOR
Intervention: Water-seal group
Number of subjects: 80
Study 7952457 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 80
Study 3302918 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin-sulfisoxazole (E/S)
Number of subjects: 119
Study 3302918 — intervention group
Group type: COMPARATOR
Intervention: Cefaclor
Number of subjects: 119
Study 3302918 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin-sulfisoxazole (E/S) and Cefaclor
Number of subjects: 119
Study 2781241 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacokinetic method for estimating hepatic plasma flow and extraction ratio of indocyanine green
Number of subjects: 0
Study 2781241 — intervention group
Group type: COMPARATOR
Intervention: Fick principle method for estimating hepatic plasma flow and extraction ratio of indocyanine green
Number of subjects: 0
Study 31508999 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical bowel preparation plus oral antibiotic bowel preparation (neomycin and metronidazole)
Number of subjects: 311
Study 31508999 — intervention group
Group type: COMPARATOR
Intervention: Mechanical bowel preparation
Number of subjects: 311
Study 30977385 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab 1200 mg every 3 weeks with chemotherapy (capecitabine or gemcitabine/carboplatin)
Number of subjects: 0
Study 30977385 — intervention group
Group type: COMPARATOR
Intervention: Placebo every 3 weeks with chemotherapy (capecitabine or gemcitabine/carboplatin)
Number of subjects: 0
Study 29806315 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic separate double-layer suture bridge technique (trial group)
Number of subjects: 54
Study 29806315 — intervention group
Group type: COMPARATOR
Intervention: Arthroscopic whole-layer suture bridge technique (control group)
Number of subjects: 54
Study 26378949 — intervention group
Group type: COMPARATOR
Intervention: Fitkids Treadmill Test (FTT)
Number of subjects: 68
Study 23385793 — intervention group
Group type: EXPERIMENTAL
Intervention: Altered spherical aberration and vision training
Number of subjects: 177
Study 23385793 — intervention group
Group type: EXPERIMENTAL
Intervention: Altered spherical aberration only
Number of subjects: 177
Study 23385793 — intervention group
Group type: EXPERIMENTAL
Intervention: Vision training only
Number of subjects: 177
Study 23385793 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 177
Study 21648012 — intervention group
Group type: EXPERIMENTAL
Intervention: Phytosterol/stanol-enriched functional foods
Number of subjects: 0
Study 21648012 — intervention group
Group type: COMPARATOR
Intervention: Pharmaceutical care
Number of subjects: 0
Study 21648012 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 21648012 — intervention group
Group type: EXPERIMENTAL
Intervention: Phytosterol/stanol users in usual care group
Number of subjects: 0
Study 18327433 — intervention group
Group type: EXPERIMENTAL
Intervention: MPH-SODAS
Number of subjects: 16
Study 18327433 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 16850006 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Number of subjects: 40
Study 16850006 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 40
Study 16128679 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg intravenously
Number of subjects: 20
Study 11230282 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C repletion with 117 mg/d for 1 month after 1 month of depletion
Number of subjects: 68
Study 9035281 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic 7.5% NaCl + 6% dextran (HSD, n = 101)
Number of subjects: 212
Study 9035281 — intervention group
Group type: COMPARATOR
Intervention: Isotonic 0.9% NaCl solutions (IS, n = 111)
Number of subjects: 212
Study 8197242 — intervention group
Group type: EXPERIMENTAL
Intervention: Toe spreader on
Number of subjects: 18
Study 8197242 — intervention group
Group type: COMPARATOR
Intervention: Toe spreader off
Number of subjects: 18
Study 3297375 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual lorazepam combined with high-dose metoclopramide (3 mg/kg) infused twice 3 h apart with i.v. dexamethasone
Number of subjects: 60
Study 3297375 — intervention group
Group type: COMPARATOR
Intervention: Sublingual lorazepam combined with high-dose metoclopramide (3 mg/kg) infused twice 3 h apart without i.v. dexamethasone
Number of subjects: 60
Study 31680180 — intervention group
Group type: EXPERIMENTAL
Intervention: Indocyanine green (ICG) administered on Day 0-3
Number of subjects: 32
Study 31680180 — intervention group
Group type: EXPERIMENTAL
Intervention: Indocyanine green (ICG) administered on Day 4-7
Number of subjects: 32
Study 31680180 — intervention group
Group type: EXPERIMENTAL
Intervention: Indocyanine green fluorescence imaging (ICG FI)
Number of subjects: 32
Study 29127786 — intervention group
Group type: EXPERIMENTAL
Intervention: ASCOS (Adolescent Smoking Curiosity Scale)
Number of subjects: 101
Study 27571099 — intervention group
Group type: EXPERIMENTAL
Intervention: Oat bran (4.5, 13.6 or 27.3 g) mixed in water
Number of subjects: 10
Study 27571099 — intervention group
Group type: EXPERIMENTAL
Intervention: Oat β‐glucan
Number of subjects: 10
Study 24014477 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic group therapy
Number of subjects: 106
Study 24014477 — intervention group
Group type: EXPERIMENTAL
Intervention: Analytic group therapy
Number of subjects: 106
Study 24014477 — intervention group
Group type: COMPARATOR
Intervention: Both treatments
Number of subjects: 106
Study 21910945 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of broccoli sprouts and GRP powder
Number of subjects: 4
Study 21910945 — intervention group
Group type: EXPERIMENTAL
Intervention: Broccoli sprouts alone
Number of subjects: 4
Study 21910945 — intervention group
Group type: EXPERIMENTAL
Intervention: GRP powder alone
Number of subjects: 4
Study 21910945 — intervention group
Group type: COMPARATOR
Intervention: GRP powder meal
Number of subjects: 4
Study 21910945 — intervention group
Group type: COMPARATOR
Intervention: Broccoli sprout meal
Number of subjects: 4
Study 20861150 — intervention group
Group type: EXPERIMENTAL
Intervention: Wuhan Smoking Prevention Program
Number of subjects: 1391
Study 20861150 — intervention group
Group type: COMPARATOR
Intervention: 30-day smokers
Number of subjects: 1391
Study 17929073 — intervention group
Group type: EXPERIMENTAL
Intervention: Strontium ranelate 2 g/day
Number of subjects: 1240
Study 17929073 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1240
Study 15962567 — intervention group
Group type: EXPERIMENTAL
Intervention: Agricultural population
Number of subjects: 0
Study 15962567 — intervention group
Group type: EXPERIMENTAL
Intervention: Age-specific fertility rate (fx)
Number of subjects: 0
Study 15962567 — intervention group
Group type: EXPERIMENTAL
Intervention: Age group 25-29 years
Number of subjects: 0
Study 15962567 — intervention group
Group type: COMPARATOR
Intervention: Comparison with national fertility
Number of subjects: 0
Study 14663654 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract EGb 761 (240 mg/day)
Number of subjects: 0
Study 14663654 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 14663654 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract EGb 761
Number of subjects: 0
Study 11380294 — intervention group
Group type: EXPERIMENTAL
Intervention: EPO (NeoRecormon) and oral iron for 4 weeks prior to surgery
Number of subjects: 31
Study 11380294 — intervention group
Group type: COMPARATOR
Intervention: Oral iron only for 4 weeks prior to surgery
Number of subjects: 31
Study 9409274 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat meals (70 g of either rapeseed oil, olive oil, sunflower oil, palm oil, or butter)
Number of subjects: 18
Study 9409274 — intervention group
Group type: COMPARATOR
Intervention: Low-fat meals (6% of energy from fat)
Number of subjects: 18
Study 8298714 — intervention group
Group type: EXPERIMENTAL
Intervention: Sandoglobulin (SG) 0.5 g/kg/day
Number of subjects: 34
Study 8298714 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentaglobin (PG) 5 ml/kg/day
Number of subjects: 34
Study 3681277 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 300 mg (H-2 receptor antagonist)
Number of subjects: 17
Study 3681277 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphenhydramine 50 mg (H-1 receptor antagonist)
Number of subjects: 17
Study 3681277 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 3681277 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined antihistamines (Diphenhydramine 50 mg and Cimetidine 300 mg)
Number of subjects: 17
Study 31647775 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial photobiomodulation (t‐PBM) with near‐infrared light (NIR), self-administered daily for 20 minutes, 830 nm peak wavelength, average irradiance 30 mW/cm2, average fluence 36 J/cm2, total energy delivered per session 2.9 kJ.
Number of subjects: 15
Study 28894551 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 143
Study 28894551 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone
Number of subjects: 143
Study 28894551 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 143
Study 25869405 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula (HFNC)
Number of subjects: 124
Study 25869405 — intervention group
Group type: COMPARATOR
Intervention: High fraction‐inspired oxygen facial mask (HFFM)
Number of subjects: 124
Study 25869405 — intervention group
Group type: EXPERIMENTAL
Intervention: HFNC
Number of subjects: 124
Study 25869405 — intervention group
Group type: COMPARATOR
Intervention: HFFM
Number of subjects: 124
Study 23931128 — intervention group
Group type: EXPERIMENTAL
Intervention: 17% EDTA
Number of subjects: 5
Study 23931128 — intervention group
Group type: EXPERIMENTAL
Intervention: BioPure MTAD
Number of subjects: 5
Study 23931128 — intervention group
Group type: COMPARATOR
Intervention: 5.25% NaOCl (Control)
Number of subjects: 5
Study 23931128 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser (1.8 W, 120 mJ, 15 Hz)
Number of subjects: 5
Study 23931128 — intervention group
Group type: EXPERIMENTAL
Intervention: Nd:YAG laser (1 W, 100 mJ, 15 Hz)
Number of subjects: 5
Study 21896838 — intervention group
Group type: EXPERIMENTAL
Intervention: pegaptanib 0.3 mg
Number of subjects: 260
Study 21896838 — intervention group
Group type: COMPARATOR
Intervention: sham injection
Number of subjects: 260
Study 19691092 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoablation
Number of subjects: 244
Study 19691092 — intervention group
Group type: COMPARATOR
Intervention: EBRT
Number of subjects: 244
Study 18007136 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparins
Number of subjects: 0
Study 18007136 — intervention group
Group type: EXPERIMENTAL
Intervention: Fondaparinux or danaparoid
Number of subjects: 0
Study 18007136 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term low-molecular-weight heparins therapy
Number of subjects: 0
Study 18007136 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium vitamin D supplementation during pregnancy
Number of subjects: 0
Study 15136618 — intervention group
Group type: EXPERIMENTAL
Intervention: Salvage index < 0.5
Number of subjects: 765
Study 15136618 — intervention group
Group type: COMPARATOR
Intervention: Salvage index >= 0.5
Number of subjects: 765
Study 15136618 — intervention group
Group type: EXPERIMENTAL
Intervention: Myocardial salvage index
Number of subjects: 765
Study 15136618 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial perfusion defect
Number of subjects: 765
Study 15136618 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 765
Study 11297307 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese herbal medicine
Number of subjects: 116
Study 11297307 — intervention group
Group type: COMPARATOR
Intervention: Inactively treated patients
Number of subjects: 116
Study 9678815 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg o.m., amoxycillin 500 mg q.d.s. and secnidazole 2 g on alternate days for 2 weeks
Number of subjects: 60
Study 9678815 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg o.m., clarithromycin 500 mg b.d. and secnidazole 2 g on alternate days for 1 week
Number of subjects: 60
Study 9678815 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg o.m., pefloxacin 400 mg o.m. and secnidazole 2 g on alternate days for 2 weeks
Number of subjects: 60
Study 9678815 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall ulcer healing rate
Number of subjects: 60
Study 8305389 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention debulking surgery
Number of subjects: 79
Study 8305389 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 79
Study 2498449 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2MV
Number of subjects: 42
Study 2498449 — intervention group
Group type: COMPARATOR
Intervention: IMV
Number of subjects: 42
Study 2498449 — intervention group
Group type: COMPARATOR
Intervention: TTM
Number of subjects: 42
Study 31898517 — intervention group
Group type: COMPARATOR
Intervention: Patient advice and an insole
Number of subjects: 180
Study 31898517 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient advice, an insole, and self-dosed heavy-slow resistance training (heel raises)
Number of subjects: 180
Study 31898517 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient advice, an insole, heavy-slow resistance training, and an ultrasound-guided corticosteroid injection
Number of subjects: 180
Study 31205144 — intervention group
Group type: EXPERIMENTAL
Intervention: 11C-methionine PET/CT
Number of subjects: 19
Study 31205144 — intervention group
Group type: EXPERIMENTAL
Intervention: 11C-choline PET/CT
Number of subjects: 19
Study 28437667 — intervention group
Group type: EXPERIMENTAL
Intervention: Ingroup perception (high entitativity, low group value)
Number of subjects: 60
Study 28437667 — intervention group
Group type: EXPERIMENTAL
Intervention: Ingroup perception (low entitativity)
Number of subjects: 60
Study 25201055 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialist health service use
Number of subjects: 162
Study 25201055 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental mental health problems
Number of subjects: 162
Study 25201055 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulant medication prescription
Number of subjects: 162
Study 24358625 — intervention group
Group type: EXPERIMENTAL
Intervention: In-office balloon dilation of maxillary sinus ostia and ethmoid infundibula
Number of subjects: 74
Study 21685533 — intervention group
Group type: EXPERIMENTAL
Intervention: Abacavir + Lamivudine (ABC+3TC)
Number of subjects: 62
Study 21685533 — intervention group
Group type: COMPARATOR
Intervention: Tenofovir + Emtricitabine (TDF+FTC)
Number of subjects: 62
Study 21685533 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 62
Study 19622125 — intervention group
Group type: EXPERIMENTAL
Intervention: Apligraf (n=17)
Number of subjects: 20
Study 19622125 — intervention group
Group type: COMPARATOR
Intervention: Conventional management (n=4)
Number of subjects: 20
Study 19622125 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiersch (n=1)
Number of subjects: 20
Study 19622125 — intervention group
Group type: EXPERIMENTAL
Intervention: HR‐US monitoring
Number of subjects: 20
Study 17121312 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3% triclosan/copolymer dentifrice
Number of subjects: 140
Study 17121312 — intervention group
Group type: COMPARATOR
Intervention: Placebo dentifrice
Number of subjects: 140
Study 15271870 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipiodol flushing
Number of subjects: 158
Study 15271870 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 158
Study 11407953 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 109
Study 11407953 — intervention group
Group type: COMPARATOR
Intervention: Lamotrigine
Number of subjects: 109
Study 9136492 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 20
Study 9136492 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextroamphetamine (DEX)
Number of subjects: 20
Study 9136492 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20